Trimble's closing the loop Autodesk can't close

Trimble is building the construction AI moat Autodesk can't buy its way around

Trimble (NASDAQ:TRMB) had a good quarter. Revenue up 12% to $940 million, ARR at a record $2.435 billion growing 13%, EPS beating the top of guidance by seven cents, full-year outlook raised. CEO Rob Painter was audibly pleased with himself on the call, which is usually a yellow flag. In this case the numbers back him up.

But the beat-and-raise is table stakes. The thing worth paying attention to is what Trimble did structurally in the same quarter: it acquired Document Crunch and announced a Claude integration from Anthropic (NASDAQ:AIG partner, private company). Put those two moves together and a specific competitive picture starts to form.

Document Crunch is AI-native contract analysis software for construction. It reads project contracts, flags risk clauses, and surfaces compliance obligations that typically get buried in hundred-page documents and ignored until a subcontractor dispute surfaces six months into a job. That's not a niche problem. Construction is one of the most litigious industries on earth, and most of that litigation traces back to contract language that nobody actually read at the right time.

Here's the chain reaction. Trimble already owns the field data layer through its machine control and GPS positioning systems. It owns a large slice of the project management and estimating layer through Viewpoint and Trimble ProjectSight. It's been pushing into BIM through its Tekla platform. What it didn't have was the contract origination layer, where a project's obligations are first defined. Document Crunch closes that gap.

So now Trimble can theoretically close a loop that no other platform has closed: a construction contract gets analysed at signing, compliance obligations get attached to project milestones in the project management system, field machines get instructions derived from the BIM model, and any deviation from plan creates a traceable record that connects back to the original contract language. That's a closed data loop across a project's entire lifecycle, and if Trimble can actually execute it, switching costs become severe.

The downstream problem for Autodesk (NASDAQ:ADSK) is real and worth sitting with. Autodesk has Procore as a competitive threat in construction project management. Now it also has Trimble building a construction-specific AI layer that ties contract compliance to field operations. Autodesk's platform is strong but generalist. Trimble is going narrow and deep in construction in a way that's genuinely hard to replicate without acquisitions, and the right acquisitions in this space are now gone.

The 71% gross margin and 27.4% EBITDA margin Painter was so visibly excited about tell you something important: this is a software business wearing the clothes of a hardware company, and the market still prices it with some hardware skepticism. ARR at $2.435 billion growing 13% is the number that matters for where this goes. If the Document Crunch integration works and construction firms start treating Trimble's platform as non-optional compliance infrastructure, that ARR number accelerates.

The CFO flagged Middle East conflict and tariff uncertainty as conservatism levers in the back-half guide. That's fair, and hardware visibility is genuinely harder to call. But the software trajectory here is the story, and on that front Painter was right to sound pleased.

✦

Quick Takes

Three more stories worth knowing about

AIG's Blackstone play is smarter than it looks on the surface

American International Group (NYSE:AIG) held what amounted to an eight-year accountability session on its investor day, and the numbers held up. The target that deserves more attention is the Blackstone SPV: AIG has created a captive reinsurer that's also the second-largest new Lloyd's syndicate ever. That gives AIG permanent dedicated capacity plus fee income on its own risk. Most insurance investors focus on the 20% EPS CAGR through 2027 and the sub-30% expense ratio targets. The structural advantage is in the capacity arrangement, and it won't show up cleanly in any single quarterly line.

Vertex's T1D pivot could double its addressable market overnight

Vertex Pharmaceuticals (NASDAQ:VRTX) raised full-year guidance to $13.1-13.2 billion and Cystic Fibrosis franchise is growing as expected, but the signal worth tracking is the Type O pivot in their T1D program. VX-880 successor VX-017 as a blood type O universal donor cell would open the addressable population from roughly 60,000 patients to 120,000, and CEO Reshma Kewalramani said explicitly she's 'very excited about the opportunity to perhaps bring Type O out first.' That is not hedging language from a CEO who chooses words carefully. Watch for timeline disclosure on VX-017 in coming quarters.

Molson Coors' summer numbers have a six-week window to actually show up

Molson Coors (NYSE:TAP) kept guidance intact and talked up the World Cup and America's 250th anniversary as summer tailwinds. The problem is the Q2 shipment hole, down 6-9% against brand volume, caused by glass supply constraints and planned brewery downtime. Management has a narrow window for the summer commercial program to show in actual financial results before the year-ago comparables get harder. The Monaco RTD acquisition adds immediate convenience channel scale, and 80-plus dedicated RTD sales reps is meaningful execution muscle. Whether that's enough to cover the shipment gap is the question the Q3 call will answer.

✦

Overlooked Stock

CRDO

Credo Technology Group Holding Ltd

Credo Technology Group (NASDAQ:CRDO) sits in one of the most consequential spots in AI infrastructure and still flies under most retail radars. The company makes high-speed connectivity chips, specifically active electrical cables and SerDes technology, that solve a specific thermal and power problem inside hyperscale AI clusters. As GPU clusters scale from hundreds to tens of thousands of accelerators, copper interconnects generate heat that optical can't solve cheaply at every link, and Credo's AEC solutions thread that needle. The customer list includes Microsoft and Amazon, which tells you the product works at the scale that matters. Score of 91 in our system, True North tier. Revenue is growing fast but the company is still small enough that a single hyperscaler acceleration in capex spending moves the numbers materially. Worth understanding before the next AI infrastructure spending cycle makes the entry point considerably less comfortable.

The Contrarian Take

The Clorox turnaround thesis is built on an oil price assumption that's already wrong

The Clorox (NYSE:CLX) recovery narrative rests on a gross margin bridge that assumes crude oil at $90 a barrel. Crude has been trading well below that for months. You'd think a lower oil price helps a consumer staples company trying to recover margins, and on one level it does. The problem is that the $90 assumption is baked into over $200 million in projected cost headwinds for the year, more than double Clorox's historical range, front-loaded into H1. If management built the bridge conservatively on oil and wrong on everything else, the recovery is real. But a CEO search mid-transformation, fresh step cat litter still bleeding share, and a CFO who ran noticeably faster through the cost section than the rest of his prepared remarks are not the hallmarks of a clean execution story. The consensus sees a recovering consumer staples name. What's actually there is a company that needs crude to stay cheap, a new CEO to arrive quickly, and litter to stop losing ground, all at once.